Optimizing Immunity Fin ‘No Antibiotics Ever’ And‘Reduced Use’ Broiler flocks

Total Page:16

File Type:pdf, Size:1020Kb

Optimizing Immunity Fin ‘No Antibiotics Ever’ And‘Reduced Use’ Broiler flocks POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY Optimizing immunity fin ‘no antibiotics ever’ and‘reduced use’ broiler flocks july 2017 • INDIANAPOlIS, INDIANA P O U - 0 0 0 9 4 POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY Jon Schaeffer, DVM, PHD Director, Poultry Veterinary Services, Zoetis Inc. [email protected] • zoetisus.com/foodsafety WELCOME The growing trend toward “no antibiotics ever” and “reduced use” production systems has prompted poultry companies to rethink their traditional disease-management practices. When flocks are raised with few or no antibiotics, they’re naturally more susceptible to diseases caused by primary or secondary infections. This has presented a huge challenge for poultry veterinarians. alternative therapies have shown potential, but reports from the field — both scientific and anecdotal — show they’ve also been inconsistent. Making refinements in nutrition, stocking rates and housing may help to reduce disease pressure. But in the end, finding ways to optimize immunity and give broilers more “staying power” could be the best strategy for maintaining the health and welfare of these birds. To help the poultry industry meet this goal, we brought together an all-star team of experts with expertise in three diseases affecting the broiler’s immune system — IBD, Marek’s and reovirus — to talk about what producers can do now to raise the bar for protection and flock welfare. This booklet presents highlights from that lively and informative discussion. Special thanks to the participants for sharing their insights and expertise. Sponsored by f Optimizing immunity in ‘no antibiotics ever’ and‘reduced use’ broiler flocks TABLE OF CONTENTS 4 PANELISTS 6 BUILDING A STRONGER BIRD 9 INFECTIOUS BURSAL DISEASE 20 REOVIRUS 26 MAREK’S DISEASE 29 WRAPPING UP POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY MARK BURLESON, DVM KALEN COOKSON, DVM ELIZABETH DALE, DVM DARAL JACKWOOD, PHD JEAN SANDER HOLLY SELLERS, DVM JOHN SMITH, DVM GUILLERMO ZAVALA, DVM 4 f Optimizing immunity in ‘no antibiotics ever’ and‘reduced use’ broiler flocks PANELISTS Mark BUrlesOn, DVM Wayne Farms kalen COOksOn, DVM Zoetis elizaBeth Dale, DVM Pilgrim’s Daral JaCkwOOD, PhD Ohio State University hOlly sellers, DVM University of Georgia JOhn sMith, DVM Alectryon, LLC GUillerMO zaVala, DVM Avian Health International, LLC MODERATOR: Jean sanDer Zoetis 5 POULTRY HEALTH T ODAY BUILDING A STRONGER BIRD 6 f Optimizing immunity in ‘no antibiotics ever’ and‘reduced use’ broiler flocks IBD is one of those diseases that will be here long after “ all of us are gone. It’s never going to go away. GUillerMO zaVala , D V M ” SANDER reovirus is a little bit more inconsistent — control of these viruses is therefore ? Dr. Zavala, would you tell us a bit about some strains are immunosuppressive critical — and we have the tools we need how control of immunosuppressive and some are not. Immunosuppressive to protect against the immunosuppressive reoviruses, like IBD, may affect B cells. diseases they cause. We don’t always diseases such as infectious bursal They cause bursal atrophy, for example, protect birds against them 100% the way disease (IBD), reovirus and Marek’s can and reduce the ability of the bird to we’d like to, but for the most part, the help us produce a more resilient bird produce immunoglobulins against vaccines we have for use in the field are with a stronger immune system? specific disease agents. good tools. ZAVALA Marek’s disease also affects B cells, IBD is one of those diseases that will be impairing the bird’s ability to produce SANDER here long after all of us are gone. It’s never sufficient antibodies to a number of ? Can vaccination against viral going to go away. It affects B cells and different infectious disease agents. It can diseases help reduce the incidence impairs their ability to produce specific impair the ability of T cells to function of secondary bacterial infections antibodies that have high affinity for very properly, which help coordinate the bird’s and, in that way, reduce the need specific disease agents. immune responses. for antibiotics? Protecting birds against Marek’s disease is a fourth very, very critical immuno- JACKWOOD absolutely critical if, for example, we’re to suppressive agent is chicken infectious When we’re talking about vaccines for reduce condemnations due to neoplasia in anemia virus (caV). It can interact immunosuppressive diseases like IBD, the processing plant. It’s also critical for with any or all of these other viruses reovirus and Marek’s, I think we can do protecting the immune system. and predispose birds to secondary a better job than what we’re doing now. opportunistic infections. It can infect If we can prevent birds from becoming and destroy bone marrow cells. immune-suppressed and getting second- The result is increased bacterial ary bacterial infections, we may be able to infection and increased severity of get away with using fewer antibiotics. any infectious disease. continued 7 POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY BUILDING A STRONGER BIRD ...it’s important to manage our secondary bacterial levels, “ and even bronchitis. kalen COOksOn, DVM ” SANDER broiler flock we knew had low reovirus SANDER ? Should efforts to build immunity titers and challenged half of them with ? Dr. Dale, according to published in broilers start with the breeder reovirus at 3 days of age and then IBD reports, Pilgrim is the second program? virus and caV at 7 days. and the results of largest producer in the uS, and that, from a viral standpoint, is that we got about 24% of your production is now SMITH about 10% weight suppression, probably “no antibiotics ever.” Have you Absolutely. The key to controlling diseases from the reovirus challenge, and 50% of seen a relationship between the like IBD or reovirus, at least under US the birds were infected with aL-2 by 2 management of these three diseases weeks of age. So IBD virus was also conditions, is hyper-immunization of the and the staying power of your flocks, probably a factor. hen using strains that are as close as and does it differ in antibiotic-free possible to your resident challenge strains. production systems versus on top of that, we challenged all the birds conventional production systems? DALE with a pathogenic Escherichia coli using If the bird is immune-compromised or either a high dose of about 8 logs or a low overwhelmed by conditions in the dose of 5 logs. Well, there wasn’t much DALE difference in the high-dose E. coli birds — environment, you can use the best The management of those three diseases as if even the immune-intact birds were vaccines in the world but they’re not is just as important in our conventional just as overwhelmed by the high E. coli going to elicit an appropriate response, systems. These problems lead to morbidity challenge. But in the low-dose E. coli and a bacterial challenge will break and mortality in both types of systems. birds, we still had significant levels of through pretty easily. however, it’s not as easy to prevent E. coli disease in the virally challenged secondary bacterial issues due to birds and no E. coli in the birds that immunosuppression in antibiotic-free COOKSON weren’t immune suppressed. So I think production systems. I’ll just share a study we performed a there’s information in that, that can kind of fit into our paradigms that we’re few years ago at auburn University careful management throughout the facing today. You know, how it’s important because I think it illustrates the interaction entire production process is needed to to manage our secondary bacterial between virally induced immune ensure we get the vaccine reaction we levels, and even bronchitis. It’s still very suppression and susceptibility to bacterial need to elicit adequate immunity, whether 1 important that we manage our immune challenge. In this study, we picked a that’s in breeders, at the hatchery or in health programs, as well. the broiler house. 8 INFECTIOUS BURSAL DISEASE 9 POULTRY HEALTH HIGHLIGHTS OF A ROUNDTABLE DISCUSSION T ODAY INFECTIOUS BURSAL DISEASE SANDER you don’t have B cells reaching the sec- The key to successful breeder vaccination ? Dr. jackwood, can you expand on ondary lymphoid organs yet. They’re con- is having breeder birds that aren’t IBD and tell us more about how it centrated in the bursa, and if they’re immune-suppressed to begin with and contributes to immune suppression? destroyed, you don’t have any more cells that have a fully functioning immune to repopulate — resulting in permanent system so they can respond to vaccines. JACKWOOD immune suppression where antibodies You need to get the titers of antibodies The virus infects immature B cells in the can’t be produced. very high so breeders pass those bursa of fabricius. Ultimately, what you antibodies on to broiler chicks through end up with is a bird with a diminished It’s important to note that the T-cell the yolk. ability to produce antibodies. population is also affected by IBD so you also see some cellular immune It’s been shown fairly well that if you have however, the severity of compromise suppression in these birds. (T cells are high serum antibodies in your breeders, depends on the timing of infection. Let’s critical for fighting bacterial infections) . you will have high antibodies in the say the bird is 14 days or older. You’ll broilers when they hatch. The issue with get a depopulation of bursa B cells and vaccination of breeders, as Dr. Smith you’ll get immune suppression, but it’s a SANDER mentioned, is that you want to make sure transient suppression.
Recommended publications
  • Antibody Responses in Furunculosis Patients Vaccinated with Autologous Formalin-Killed S
    Antibody responses in furunculosis patients vaccinated with autologous formalin-killed S. Holtfreter, J. Jursa-Kulesza, H. Masiuk, N. J. Verkaik, C. Vogel, J. Kolata, M. Nowosiad, L. Steil, W. Wamel, A. Belkum, et al. To cite this version: S. Holtfreter, J. Jursa-Kulesza, H. Masiuk, N. J. Verkaik, C. Vogel, et al.. Antibody responses in furunculosis patients vaccinated with autologous formalin-killed. European Journal of Clinical Microbiology and Infectious Diseases, Springer Verlag, 2011, 30 (6), pp.707-717. 10.1007/s10096-010- 1136-3. hal-00690187 HAL Id: hal-00690187 https://hal.archives-ouvertes.fr/hal-00690187 Submitted on 22 Apr 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 Antibody responses in furunculosis patients vaccinated with autologous 2 formalin-killed Staphylococcus aureus 3 4 Silva Holtfreter*1, 1,, Joanna Jursa-Kulesza2, Helena Masiuk2, Nelianne J. Verkaik3, Corne de Vogel3, Julia 5 Kolata1, Monika Nowosiad2, Leif Steil4, Willem van Wamel3, Alex van Belkum3, Uwe Völker4, Stefania 6 Giedrys-Kalemba2, Barbara M. Bröker1 7 8 1 Institute of Immunology and Transfusion Medicine, University of Greifswald, Germany 9 2 Department of Microbiology and Immunology, Pomeranian Medical University, Szczecin, Poland 10 3 Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The 11 Netherlands 12 4 Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald, Germany 13 14 Corresponding author: 15 Dr.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,834,015 Oleske Et Al
    USOO5834O15A United States Patent (19) 11 Patent Number: 5,834,015 Oleske et al. (45) Date of Patent: Nov. 10, 1998 54 PROTEIN-LIPID VESICLES AND Charlotte R. Kensil et al, Separation and Characterization of AUTOGENOUS WACCINE COMPRISING THE Saponins with Adjuvant Activity from Quillaia Saponaria SAME Molina Cortex, The Journal of Immunology, vol. 146, pp. 431–437, No. 2, Jan. 15, 1991. 75 Inventors: James M. Oleske, Morris Plains; Jonas E. Salk, M.D. with Mary Contakos et al, Use of Thomas N. Denny, Cranford; Anthony Adjuvants in Studies on Influenza Immunization, J.A.M.A., J. Scolpino, Ramsey; Eleonora vol. 151, No. 14, pp. 1169–1175, Apr. 4, 1953. FeketeoVa, Harrison; Susan Barney S. Graham et al, Augmentation of Human Immuno Gould-Fogerite; Raphael J. Mannino, deficiency Virus Type 1 Neutralizing Antibody by Printing both of Annandale, all of N.J. with gp160 Recombinant Vaccinia and Boosting with 73 Assignees: Albany Medical College, Albany, N.Y.; rgp160 in Vaccinia-Naive Adults, The Journal of Infectious University of Medicine and Dentistry Diseases, 1993, vol. 167, pp. 533–537. of New Jersey, Newark, N.J. E. Celis et al., Regulation of the Human Immune Response to HBSAg: Effects of Antibodies and Antigen Conformation 21 Appl. No.: 712,020 in the Stimulation of Helper T Cells by HBSAg, Hepatology, vol. 5, 744–751, 1985. 22 Filed: Sep. 11, 1996 Jonas Salk, Prospects for the Control of AIDS by Immuniz (51) Int. Cl." ..................................................... A61K 9/127 ing Seropositive Individuals, Nature, vol. 327, Jun. 1987, 52 U.S. Cl. ....................... 424/450; 424/188.1; 424/812; pp.
    [Show full text]
  • A Review of Fish Vaccine Development Strategies: Conventional Methods and Modern Biotechnological Approaches
    microorganisms Review A Review of Fish Vaccine Development Strategies: Conventional Methods and Modern Biotechnological Approaches Jie Ma 1,2 , Timothy J. Bruce 1,2 , Evan M. Jones 1,2 and Kenneth D. Cain 1,2,* 1 Department of Fish and Wildlife Sciences, College of Natural Resources, University of Idaho, Moscow, ID 83844, USA; [email protected] (J.M.); [email protected] (T.J.B.); [email protected] (E.M.J.) 2 Aquaculture Research Institute, University of Idaho, Moscow, ID 83844, USA * Correspondence: [email protected] Received: 25 October 2019; Accepted: 14 November 2019; Published: 16 November 2019 Abstract: Fish immunization has been carried out for over 50 years and is generally accepted as an effective method for preventing a wide range of bacterial and viral diseases. Vaccination efforts contribute to environmental, social, and economic sustainability in global aquaculture. Most licensed fish vaccines have traditionally been inactivated microorganisms that were formulated with adjuvants and delivered through immersion or injection routes. Live vaccines are more efficacious, as they mimic natural pathogen infection and generate a strong antibody response, thus having a greater potential to be administered via oral or immersion routes. Modern vaccine technology has targeted specific pathogen components, and vaccines developed using such approaches may include subunit, or recombinant, DNA/RNA particle vaccines. These advanced technologies have been developed globally and appear to induce greater levels of immunity than traditional fish vaccines. Advanced technologies have shown great promise for the future of aquaculture vaccines and will provide health benefits and enhanced economic potential for producers. This review describes the use of conventional aquaculture vaccines and provides an overview of current molecular approaches and strategies that are promising for new aquaculture vaccine development.
    [Show full text]
  • Best-Practice Framework for the Use of Vaccines in Animals
    Best-practice framework for the use of vaccines in animals EPRUMA best-practice framework 1 CONTENTS Introduction ................................................................................ 2 About vaccines ........................................................................... 3 Animal vaccination as part of an overall health strategy, prevention plans and responsible use ....................................... 4 Proper vaccination: recommendations.... .................................. 5 Conclusions ................................................................................ 7 INTRODUCTION EPRUMA promotes the responsible use of medicines in animals (www.epruma.eu) and shares information on best practices to prevent, control and treat animal diseases, supporting animal health and welfare, contributing to food safety, and safeguarding human wellbeing and public health. Within EPRUMA best practice guidelines, the and control infectious diseases, vaccination role of vaccination has always been highlighted. improves animal health and reduces the need Through this document, EPRUMA partners for treatment, while contributing to food safety wish to raise awareness on the benefits of and public health. vaccination, and recommend best practices for Nevertheless, the benefits of vaccination vaccine use to ensure optimal animal health. have been questioned recently by anti- vaccine pressure groups. A survey conducted Infectious disease prevention can be achieved among citizens in 2016 showed that 66% of through a combination of measures,
    [Show full text]
  • Elisabeth Erlacher-Vindel, World Organisation for Animal
    Elisabeth Erlacher-Vindel Head of the Antimicrobial Resistance & Veterinary Products Department Prioritization of Vaccines to Reduce Antibiotic use in Animals PACCARB Meeting Washington, 30 January 2019 World Organisation for Animal Health (OIE) 182 Member Countries 301 75 Reference Centres Partner organisations World Organisation for Animal Health 12 Headquarters Regional & Sub-regional Paris Representations “to improve animal health, veterinary public health and animal welfare worldwide” World Organisation for Animal Health · Protecting animals, Preserving our future | 2 OIE ad hoc Groups The OIE convened two ad hoc Groups to provide guidance on prioritisation of diseases for which the use of vaccines could reduce antimicrobial use in animals: • pigs, poultry and fish (April 2015) http://www.oie.int/en/standard-setting/specialists-commissions-working-groups/scientific- commission-reports/ad-hoc-groups-reports/ • cattle, sheep and goats (May 2018) http://www.oie.int/standard-setting/specialists-commissions-working-groups/scientific- commission-reports/ad-hoc-groups-reports/ World Organisation for Animal Health · Protecting animals, Preserving our future | 3 6.1. Key principles adopted In order to facilitate identification of infections where new or improved vaccines would have the maximum potential to reduce antibiotic use, a number of key considerations were agreed and applied: 1. Identification of the most prevalent and important bacterial infections in chickens, swine, and identification of fish species that are commonly farmed and associated with high antibiotic use, and associated prevalent bacterial infections in those species. 2. Identification of common non-bacterial infections in chicken, swine and fish (e.g. protozoal, viral) showing clinical signs that trigger empirical antibiotic treatment (e.g.
    [Show full text]
  • Optimal Use of Vaccines for Control of Influenza a Virus in Swine
    Vaccines 2015, 3, 22-73; doi:10.3390/vaccines3010022 OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Review Optimal Use of Vaccines for Control of Influenza A Virus in Swine Matthew R. Sandbulte, Anna R. Spickler, Pamela K. Zaabel and James A. Roth * Center for Food Security and Public Health, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA; E-Mails: [email protected] (M.R.S.); [email protected] (A.R.S.); [email protected] (P.K.Z.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-515-294-8459. Academic Editor: Sarah Gilbert Received: 4 December 2014 / Accepted: 19 January 2015 / Published: 30 January 2015 Abstract: Influenza A virus in swine (IAV-S) is one of the most important infectious disease agents of swine in North America. In addition to the economic burden of IAV-S to the swine industry, the zoonotic potential of IAV-S sometimes leads to serious public health concerns. Adjuvanted, inactivated vaccines have been licensed in the United States for over 20 years, and there is also widespread usage of autogenous/custom IAV-S vaccines. Vaccination induces neutralizing antibodies and protection against infection with very similar strains. However, IAV-S strains are so diverse and prone to mutation that these vaccines often have disappointing efficacy in the field. This scientific review was developed to help veterinarians and others to identify the best available IAV-S vaccine for a particular infected herd. We describe key principles of IAV-S structure and replication, protective immunity, currently available vaccines, and vaccine technologies that show promise for the future.
    [Show full text]
  • Vaccines As Alternatives to Antibiotics for Food Producing Animals
    Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions Karin Hoelzer, Lisa Bielke, Damer P. Blake, Eric Cox, Simon M. Cutting, Bert Devriendt, Elisabeth Erlacher-Vindel, Evy Goossens, Kemal Karaca, Stephane Lemiere, et al. To cite this version: Karin Hoelzer, Lisa Bielke, Damer P. Blake, Eric Cox, Simon M. Cutting, et al.. Vaccines as alterna- tives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet- erinary Research, BioMed Central, 2018, 49 (1), pp.70. 10.1186/s13567-018-0561-7. hal-02973513 HAL Id: hal-02973513 https://hal.archives-ouvertes.fr/hal-02973513 Submitted on 21 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Hoelzer et al. Vet Res (2018) 49:70 https://doi.org/10.1186/s13567-018-0561-7 REVIEW Open Access Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions Karin Hoelzer1* , Lisa Bielke2, Damer P. Blake3, Eric Cox4, Simon M. Cutting5, Bert Devriendt4, Elisabeth Erlacher‑Vindel6, Evy Goossens7, Kemal Karaca8, Stephane Lemiere9, Martin Metzner10, Margot Raicek6, Miquel Collell Suriñach11, Nora M.
    [Show full text]
  • Bovine Vaccines and Herd Vaccination Programs
    Bovine Vaccines and Herd Vaccination Programs Victor S. Cortese, Consulting Editor With the increasing size of today's cattle operations and the extensive movement of cattle, disease exposure continues to occur at a high rate. These exposures often put pressure on the efficacy of the vaccines used and may give field experience as to how well they can protect cattle. The wide diversity in uses of cattle and management practices makes a single vaccination protocol impossible for all cattle production systems. Today it is even more important to scientifically choose a vaccine or design a vaccination program based on good information. When designing programs, several variables must be considered1: • The presence and degree of challenge of the particular diseases on the farm or ranch (Boxes 48-1 and 48-2) • Management practices on the facility that support or hinder vaccination programs • The times or ages when disease problems occur and whether the diseases are associated with any stressors • The immune system components necessary to afford protection against various diseases • Some basic immunologic concepts • The information available on products being considered and the source and quality of the information • Required vaccines for a particular use of the animal (e.g., 4-H shows) Challenge The level of disease challenge and the degree of protection continually fluctuate. Biological variability makes the degree of protection different in every vaccinated animal. The same is true for the level of exposure to a pathogen. Overwhelming challenge can override immunity and lead to disease even in well-vaccinated animals.2 Timing of Disease On many farms, certain diseases occur at consistent times.
    [Show full text]
  • Current Status of Fish Vaccines in Japan
    Fish and Shellfish Immunology 95 (2019) 236–247 Contents lists available at ScienceDirect Fish and Shellfish Immunology journal homepage: www.elsevier.com/locate/fsi Full length article Current status of fish vaccines in Japan T ∗ Yuta Matsuura, Sachiko Terashima, Tomokazu Takano, Tomomasa Matsuyama Research Center of Fish Diseases, National Research Institute of Aquaculture, Japan Fisheries Research and Education Agency, Minami.-Ise, Mie, Japan ARTICLE INFO ABSTRACT Keywords: Aquaculture is an important industry in Japan for the sustainable production of fish. It contributes to the di- Aquaculture versity of Japanese traditional food culture, which uses fish such as “sushi” and “sashimi”. In the recent Fish diseases aquaculture setting in Japan, infectious diseases have been an unavoidable problem and have caused serious Fish vaccines economic losses. Therefore, there is an urgent need to overcome the disease problem to increase the productivity Bacterial hemolytic jaundice of aquaculture. Although our country has developed various effective vaccines against fish pathogens, which Bacterial cold-water disease have contributed to disease prevention on fish farms, infectious diseases that cannot be controlled by conven- Erythrocytic inclusion body syndrome ff Nocardia tional inactivated vaccines are still a problem. Therefore, other approaches to developing e ective vaccines Piscine orthoreovirus other than inactivated vaccines are required. This review introduces the vaccine used in Japan within the context Plecoglossus altivelis poxvirus-like virus of the current status of finfish aquacultural production and disease problems. This review also summarizes the current research into vaccine development and discusses the future perspectives of fish vaccines, focusing on the problems associated with vaccine promotion in Japan.
    [Show full text]
  • Goat Vaccination
    LIVESTOCK Goat Vaccination ► The goal of vaccination is to stimulate an immune response that provides some level of protection from disease. Unfortunately, most vaccines do not achieve complete protection from infection and subsequent disease. Vaccines are expected to reduce the severity of disease in infected animals or limit the frequency of disease in the herd. Many factors, including nutrition, stresses, and the general health of animals, can influence the effectiveness of vaccination. Vaccines should be administered according to label directions and only to systemically healthy animals. Consult your veterinarian for guidance when designing and implementing a herd vaccination program. Vaccines should not be expected to eliminate all disease problems and should be considered only as a tool to be used with other management strategies to mitigate the occurrence and impacts of infectious diseases. Types of Vaccines Figure 1. Most vaccines are administered subcutaneously (SQ, under the skin), Killed Vaccines which can be performed in a triangle of skin in front of the shoulder or in the axillary (under the arm) region. Intramuscular injections should be given only in the neck Killed vaccines and toxoids consist of killed muscles, using the same injection site. microorganisms, components of pathogens, or by-products of microorganisms in combination with Modified Live Vaccines adjuvants, such as aluminum hydroxide or oil, in order Modified live vaccines (MLV) contain a small quantity to produce a sufficient immune response. The major of virus or bacteria that has been altered so that it advantages of killed vaccines are safety and stability of no longer is capable of causing clinical disease.
    [Show full text]
  • Update on Streptococcus Suis Research and Prevention In
    pathogens Conference Report Conference Report Update on StreptococcusUpdate on suisStreptococcus Research and suis Research and Prevention Prevention in thein Era the of Era Antimicrobial of Antimicrobial Restriction: Restriction: 4th y † 4th InternationalInternational Workshop on Workshop S. suis on S. suis 1, 2,‡ 1, 3,‡ 2, 4,‡ 3, 4, Mariela Segura *, Virginia AragonMariela Segura, Susan L.*, Brockmeier Virginia Aragon , Conniez , Gebhart Susan L. Brockmeier, Astrid de z, Connie Gebhart z , 5,‡ 6,‡ 7,‡5, 8,‡6, 9,‡ 7, 8, Greeff , Anusak Kerdsin , AstridMark A de O’Dea Greeff , zMasatoshi, Anusak Kerdsin Okura ,z Mariette, Mark Saléry A O’Dea , z , Masatoshi Okura z, 10,‡ 9, 11,‡ 12,‡10, 13,14,‡ 11, 12, Constance Schultsz , Peter Valentin-WeigandMariette Saléry z, Constance, Lucy A. SchultszWeinert ,z ,Jerry Peter M. Valentin-Weigand Wells and z, Lucy A. Weinert z, 1, 13,14, 1, Marcelo Gottschalk * Jerry M. Wells z and Marcelo Gottschalk * 1 Research Group on Infectious Diseases1 Research in Producti Groupon on Animals Infectious and Diseases Swine and in Production Poultry Infectious Animals Diseases and Swine and Poultry Infectious Diseases Research Centre, Faculty of VeterinaryResearch Medicine, Centre, University Faculty of of Veterinary Montreal, Medicine, St-Hyacinthe, University QC J2S of 2M2, Montreal, St-Hyacinthe, QC J2S 2M2, Canada Canada 2 IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de 2 IRTA, Centre de Recerca en SanitatBarcelona, Animal (CReSA, 08193 Bellaterra, IRTA-UAB), Spain; Campus [email protected] de la Universitat Autònoma de Barcelona, Bellaterra 08193, Spain;3 USDA,[email protected] ARS, National Animal Disease Center, Ames, IA 50010, USA; [email protected] 3 USDA, ARS, National Animal Disease4 College Center, of Veterinary Ames, IA Medicine,50010, USA; University [email protected] of Minnesota, St.
    [Show full text]
  • Effect of Bivalent Vaccines Against Vibrio Anguillarum and Aeromonas Salmonicida Subspecie Achromogenes on Health and Survival of Turbot
    Article Effect of Bivalent Vaccines against Vibrio anguillarum and Aeromonas salmonicida Subspecie achromogenes on Health and Survival of Turbot Yolanda Torres-Corral 1,* , Albert Girons 2, Oscar González-Barreiro 3, Rafael Seoane 4 , Ana Riaza 3 and Ysabel Santos 1,* 1 Departamento de Microbiología y Parasitología, Instituto de Análisis Químico y Biológico (IAQBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain 2 Ictiovet S.L., 08025 Barcelona, Spain; [email protected] 3 Stolt Sea Farm, Edificio Quercus, 15707 Santiago de Compostela, Spain; [email protected] (O.G.-B.); [email protected] (A.R.) 4 Departamento de Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; [email protected] * Correspondence: [email protected] (Y.T.-C.); [email protected] (Y.S.) Abstract: The efficacy of intraperitoneal injection of an oil-based bivalent autogenous vaccine and the commercial vaccine AlphaJect 3000 (Pharmaq AS) to prevent atypical furunculosis and vibriosis in turbot was analyzed. The effect of both vaccines on health parameters and survival of fish after challenge with V. anguillarum and A. salmonicida subsp. achromogenes was tested. The autogenous vaccine conferred high levels of protection and long-lasting immunity against both pathogens with Citation: Torres-Corral, Y.; a single dose. However, severe side effects were observed in turbot injected with this autovaccine Girons, A.; González-Barreiro, O.; and minor negative effects with the AlphaJect 3000 vaccine and the adjuvant Montanide or Eolane. Seoane, R.; Riaza, A.; Santos, Y. Effect of Bivalent Vaccines against Vibrio All vaccinated fish showed remarkable antibody agglutination titers, higher than those of control anguillarum and Aeromonas salmonicida fish, which were maintained 160 d after vaccination.
    [Show full text]